Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

Launched by HAMILTON HEALTH SCIENCES CORPORATION · Apr 2, 2025

Keywords

ClinConnect Summary

The GAIN PC CONTROL trial is a study looking at the effects of a medication called GLP-1 receptor agonists in men who have prostate cancer and are undergoing a specific type of treatment known as androgen deprivation therapy (ADT). This therapy is used to lower testosterone levels to help slow the growth of prostate cancer. The study aims to see how this medication can help men who also have a higher body weight, as they may face additional health challenges.

To be eligible for the trial, participants must be men aged 65 to 74 who have a doctor’s diagnosis of prostate cancer and are receiving or planning to start ADT. They also need to have a higher body mass index (BMI), which is a measure of body fat based on height and weight. However, there are certain conditions that would exclude someone from joining, such as having type 1 diabetes or a history of pancreatitis. If eligible, participants will receive more information about what to expect during the trial, including any treatments or assessments they will undergo. This study is currently not recruiting participants, so more details will be provided when it begins.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Have a physician diagnosis of PC
• • Must be receiving or planned to receive ADT (gonadotropin releasing hormone agonist or antagonist ± androgen receptor pathway inhibitor)
• • Elevated BMI
• • 1. ≥30kg/m2 or
• • 2. ≥27kg/m2 in the presence of at least one of hypertension, type 2 diabetes, obstructive sleep apnea or dyslipidemia
• Exclusion Criteria:
• • Type 1 diabetes
• • Taking a GLP-1 RA
• • \<18 years of age
• • History of pancreatitis
• • Personal or family history of medullary cancer of the thyroid
• • Multiple endocrine neoplasia type 2